Engineered Extracellular Vesicles for High-Density Agonist Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic platforms for intercellular communication using extracellular vesicles face challenges in reliably targeting specific biological signals without off-target effects and achieving robust cellular responses, particularly in modulating inflammation and immune checkpoint signaling.
Innovation Solution
Engineered extracellular vesicles, or artificial synapses, are developed with vesicle targeting domains and signaling domains joined by linkers, expressed in mammalian cells, allowing for enhanced signal generation and propagation by increasing agonist presentation to support receptor clustering.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional soluble ligand targeting strategies are used, then the system is simple to implement, but the agonist presentation density is insufficient to support receptor clustering on target cells
Solution Approach 1:
The patent uses extracellular vesicles as intermediary carriers to deliver fusion proteins containing signaling domains to target cells. The vesicles act as a mediator between the agonist and target cell receptors, enabling high-density presentation of signaling molecules on the vesicle surface, which supports receptor clustering and robust signal generation without requiring direct soluble ligand application
Solution Approach 2:
The invention creates composite structures by fusing signaling domains (POI domains) with vesicle targeting domains to generate fusion proteins. These fusion proteins are then incorporated into extracellular vesicles, creating a composite system that combines the targeting capability of vesicles with the signaling function of the POI domains, achieving both high-density agonist presentation and specific target cell recognition
2Reliability
If extracellular vesicles are engineered with fusion proteins to increase agonist presentation, then receptor clustering and signal generation are enhanced, but the risk of off-target effects increases
Solution Approach 1:
The patent employs vesicle targeting domains that provide local specificity by directing the engineered extracellular vesicles to particular target cells through cell-type-specific recognition molecules. This localized targeting ensures that the high-density agonist presentation on the vesicle surface is delivered only to the intended target cells, maintaining signal generation reliability while minimizing off-target effects through spatially restricted action
3Adaptability or versatility
If fusion proteins with vesicle targeting domains are used to anchor signaling domains to the vesicle membrane, then the platform becomes more flexible and dynamic for targeted therapy, but the manufacturing complexity increases
Solution Approach 1:
The invention segments the therapeutic platform into modular components: extracellular vesicles as the delivery vehicle, vesicle targeting domains for specific cell recognition, linker sequences for flexible connection, and protein of interest domains for signaling function. This segmentation allows each component to be independently optimized and assembled, providing flexibility and adaptability for different therapeutic applications while establishing a systematic approach to manufacturing that can be standardized across different POI domains and targeting specificities
Data Source
AI summary
Described herein are compositions and techniques related to generation and therapeutic application of artificial synapses. Artificial synapses are engineered extracellular vesicles, including exosomes, which incorporate sticky binders on their surface to anchor signaling domains against biological targets, such as receptors. These engineered additives can be organized in genetic vector constructs, expressed in mammalian cells, wherein the sticky binders attach to extracellular vesicles such as exosomes, thereby presenting their joined signaling domains which are rapidly taken up by recipient cells. Artificial synapses adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation. This includes, for example, increasing density of agonist presentation to support receptor clustering—an onerous barrier for traditional receptor targeting strategies.